R. R. Camejo

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Annelot M. Dekker, A. Destée, S. Bates, 2017, The Lancet Neurology.

Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD

M. Miraldo, F. Rutten, C. Mcgrath, 2014, The European Journal of Health Economics.

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era

Helen T. Smith, Jipan Xie, E. Wu, 2020, Kidney medicine.

Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance

R. R. Camejo, H. Chung, D. Barnett, 2006, Heart.

Assessing the determinants of the potential for cost-effectiveness over time: the empirical case of COPD.

R. Herings, F. Rutten, C. Mcgrath, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis

J. Stephens, R. R. Camejo, S. Snedecor, 2014, PloS one.

The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease.

Ashutosh Kumar Singh, V. Jha, D. Wheeler, 2023, Kidney international.

Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.

M. Holmes, R. R. Camejo, M. L. Jones, 2009, Health technology assessment.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Annelot M. Dekker, A. Destée, S. Bates, 2017, The Lancet Neurology.